Ipsen claims pos­i­tive PhI­II in drug once owned by Mer­ri­mack, whose shares jump pend­ing pos­si­ble nine-fig­ure pay­out

Ipsen an­nounced a pos­i­tive late-stage read­out ear­ly Wednes­day, re­sult­ing in a de­funct biotech po­ten­tial­ly re­ceiv­ing the big bucks.

The French phar­ma an­nounced that the pri­ma­ry end­point was met in a Phase III pan­cre­at­ic can­cer tri­al, show­ing im­prove­ment in over­all sur­vival with a treat­ment reg­i­men in­clud­ing Ipsen’s irinote­can, aka Onivyde, in 770 pre­vi­ous­ly un­treat­ed pa­tients with mP­DAC, or metasta­t­ic pan­cre­at­ic duc­tal ade­no­car­ci­no­ma. There were al­so pos­i­tive da­ta in pro­gres­sion-free sur­vival, a sec­ondary ef­fi­ca­cy end­point.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER